Blood test clues could transform AFib care – but study pulled
NCT ID NCT07565337
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aimed to validate several blood biomarkers (like NT-proBNP and IL-6) to help doctors assess atrial fibrillation burden and track treatment effectiveness. Researchers planned to analyze samples from 266 patients before and after treatment. However, the study was withdrawn before any participants were enrolled, so no new insights were gained.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this research could help doctors use blood tests to better track atrial fibrillation and predict heart failure progression.
- What could go wrong
- The study was withdrawn before enrolling any participants, so no results are available. The findings may not apply to all patients with atrial fibrillation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Taiwan University Hospita
Taipei, 100, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A tiny neck implant could catch Stroke-Causing clots before they reach the brain
- Could a new injection tame atrial fibrillation?
- Which blood thinner is safer for heart patients? a Head-to-Head test
- Can a cholesterol drug keep atrial fibrillation at bay after ablation?
- Can a One-Two punch fix a leaky heart valve and restore normal rhythm?
- Could a guided Self-Care plan tame atrial Fibrillation's return?